(PSCH) S&P SmallCap Health Care - Overview
Etf: ETF, Small-Cap, Healthcare, US, S&P
Dividends
| Dividend Yield | 0.03% |
| Yield on Cost 5y | 0.03% |
| Yield CAGR 5y | 37.84% |
| Payout Consistency | 28.3% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.4% |
| Relative Tail Risk | -2.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -23.60 |
| Character TTM | |
|---|---|
| Beta | 0.882 |
| Beta Downside | 0.782 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.40% |
| CAGR/Max DD | -0.07 |
Description: PSCH S&P SmallCap Health Care December 29, 2025
The Invesco S&P Small-Cap Health Care ETF (NASDAQ: PSCH) seeks to track the S&P SmallCap 600 Health Care Index, investing at least 90 % of its assets in the index constituents-U.S. small-cap companies classified in health care under the GICS framework.
Key metrics (as of the latest public filings) show the fund holds roughly 350 stocks with an average market-cap of about $1.2 billion, a weighted expense ratio near 0.30 %, and a 12-month trailing return of ~-4 % (reflecting sector volatility). Primary drivers for this space include aging demographics, Medicare reimbursement policy shifts, and the pipeline intensity of biotech R&D, all of which tend to amplify earnings sensitivity for small-cap innovators.
If you want a deeper, data-rich view of PSCH’s risk-adjusted performance and its exposure to emerging health-care sub-themes, a quick look at ValueRay’s analytical dashboard can help you spot the next high-conviction entry point.
What is the price of PSCH shares?
Over the past week, the price has changed by -1.31%, over one month by -3.93%, over three months by +4.11% and over the past year by -7.89%.
Is PSCH a buy, sell or hold?
What are the forecasts/targets for the PSCH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 43 | -1.5% |
PSCH Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 150.1m USD (150.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 150.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 150.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.16% (E(150.1m)/V(150.1m) * Re(9.16%) + (debt-free company))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)